News & Updates

Anaphylactic reactions warranting treatment after receipt of COVID-19 mRNA vaccinations appear to be relatively rare, according to a US study presented at AAAAI 2022.

A delayed release/extended release (DR/ER) formulation of amantadine can help reduce breakthrough symptoms in Parkinson’s disease patients when the effect of levodopa therapy wears off, as shown in a recent study.

Treatment with a guideline-based thromboprophylaxis in multiple myeloma patients and the addition of pharmacy oversight to risk assessment can help reduce the risk of venous thromboembolism (VTE), suggests a recent study.

Patients with relapsed/refractory multiple myeloma (RRMM) are at greater risk of adverse events (AEs), have low overall survival (OS), and suffer a substantial economic burden, reports a study, which suggests the need for effective treatment options.

Treatment with rosuvastatin, given at moderate and high intensity doses, as well as simvastatin and atorvastatin, given at high intensity doses, modestly reduce levels of nonhigh-density lipoprotein cholesterol (non-HDL-C) in diabetic patients over 12 weeks compared with placebo, a study has shown.

For men with erectile dysfunction (ED) who show a lack of response to oral phosphodiesterase type 5 inhibitors (PDE5Is), combination therapy with topical alprostadil plus PDE5Is seems favourable, producing greater improvements in sexual function without compromising safety compared with topical alprostadil alone, as shown in a study.